Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Unit for Cell Signalling (Krauss)

5 publications found

Kierulf-Vieira KS, Sandberg CJ, Waaler J, Lund K, Skaga E, Saberniak BM, Panagopoulos I, Brandal P, Krauss S, Langmoen IA, Vik-Mo EO (2020)
A Small-Molecule Tankyrase Inhibitor Reduces Glioma Stem Cell Proliferation and Sphere Formation
Cancers (Basel), 12 (6)
DOI 10.3390/cancers12061630, PubMed 32575464

Perdreau-Dahl H, Progida C, Barfeld SJ, Guldsten H, Thiede B, Arntzen M, Bakke O, Mills IG, Krauss S, Morth JP (2020)
Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells
Commun Biol, 3 (1), 123
DOI 10.1038/s42003-020-0851-2, PubMed 32170109

Wang H, Kuusela S, Rinnankoski-Tuikka R, Dumont V, Bouslama R, Ramadan UA, Waaler J, Linden AM, Chi NW, Krauss S, Pirinen E, Lehtonen S (2020)
Tankyrase inhibition ameliorates lipid disorder via suppression of PGC-1α PARylation in db/db mice
Int J Obes (Lond)
DOI 10.1038/s41366-020-0573-z, PubMed 32317752

Waaler J, Leenders RGG, Sowa ST, Alam Brinch S, Lycke M, Nieczypor P, Aertssen S, Murthy S, Galera-Prat A, Damen E, Wegert A, Nazaré M, Lehtiö L, Krauss S (2020)
Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor
J Med Chem (in press)
DOI 10.1021/acs.jmedchem.0c00208, PubMed 32511917

Waaler J, Mygland L, Tveita A, Strand MF, Solberg NT, Olsen PA, Aizenshtadt A, Fauskanger M, Lund K, Brinch SA, Lycke M, Dybing E, Nygaard V, Bøe SL, Heintz KM, Hovig E, Hammarström C, Corthay A, Krauss S (2020)
Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
Commun Biol, 3 (1), 196
DOI 10.1038/s42003-020-0916-2, PubMed 32332858

 
Page visits: 410615